RhumbLine Advisers’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

RhumbLine Advisers’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-42,714	Closed	-$1.42M	–	4231
2024 Q3	$1.42M	Buy	42,714 +238	+0.6%	+$8.2K	﹤0.01%	2082
2024 Q2	$1.15M	Buy	42,476 +12,500	+42%	+$247K	﹤0.01%	2169
2024 Q1	$647K	Buy	29,976 +13,790	+85%	+$301K	﹤0.01%	2504
2023 Q4	$97.6K	Hold	16,186	–	–	﹤0.01%	3455
2023 Q3	$90K	Buy	16,186 +804	+5%	+$5.18K	﹤0.01%	3496
2023 Q2	$113K	Buy	+15,382	New	+$116K	﹤0.01%	3475

RhumbLine Advisers's LBPH Position: Q4 2024 in Review

RhumbLine Advisers sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 42,714 shares — an estimated $1.42M sold.

RhumbLine Advisers first reported a position in LBPH in Q2 2023 and held it in 6 quarters. The position peaked at $1.42M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

RhumbLine Advisers reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
RhumbLine Advisers sold 42,714 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.42M.
RhumbLine Advisers first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 6 quarters.
RhumbLine Advisers's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $1.42M in Q3 2024.
0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on RhumbLine Advisers's 13F filing for Q4 2024, filed 30 Jan 2025.